IQVIA
IQV stock analysis · Health Care · Life Sciences Tools & Services
As of · fund-implied per-share value
Fund holding value ÷ shares held. Not a live quote; not adjusted for later stock splits.
View SEC fund filing ↗Price × SEC outstanding shares. Shares measured 2026-04-30. Approximate; share and price dates can differ.
View share-count filing ↗DCF value
Equity cash-flow scenario · SEC outstanding shares at 2026-04-30 · -3.4% versus input cap
How this is calculated ↗Reverse DCF
Annual basis · read assumptions below
How this is calculated ↗Relative valuation
6 industry peers · median 33.2×
How this is calculated ↗Historical multiples
7 annual observations · snapshot P/E 23.7× · -38.4% versus history
How this is calculated ↗Free cash flow yield
Annual basis · read assumptions below
How this is calculated ↗ROIC / quality
Normalized tax · financing-capital proxy · short-term borrowing coverage incomplete
How this is calculated ↗Value composite
Annual basis · read assumptions below
How this is calculated ↗12–1 price momentum
Split and corporate-action verification is incomplete for these fund observations. Verified adjusted endpoints are required for 12–1 momentum.
How this is calculated ↗Asset growth
Annual basis · read assumptions below
How this is calculated ↗Net payout yield
Requires reported dividends, repurchases and issuance; missing values are not zero.
How this is calculated ↗Accrual quality
Annual basis · read assumptions below
How this is calculated ↗Fundamental momentum
Annual basis · read assumptions below
How this is calculated ↗Follow the cash
ANNUAL · USDOperating cash flow and reinvestment over time
Annual USD. Negative bars use a compressed lower scale. Hover or inspect the financial history table for exact values.
Make the assumptions yours
How sensitive is the valuation?
| Return / Growth | 3.0% | 5.0% | 7.0% |
|---|---|---|---|
| 8.0% | $234.11 | $255.44 | $278.37 |
| 10.0% | $171.55 | $186.65 | $202.86 |
| 12.0% | $135.34 | $146.86 | $159.21 |
Annual financial history
Open SEC filings ↗| Fiscal year-end | Revenue | Net income | Operating cash flow | Capital expenditure | Assets |
|---|---|---|---|---|---|
| 2025-12-31 | 16.3B | 1.4B | 2.7B | 603M | 29.9B |
| 2024-12-31 | 15.4B | 1.4B | 2.7B | 602M | 26.9B |
| 2023-12-31 | 15B | 1.4B | 2.1B | 649M | 26.7B |
| 2022-12-31 | 14.4B | 1.1B | 2.3B | 674M | 25.3B |
| 2021-12-31 | 13.9B | 971M | 2.9B | 640M | 24.7B |
| 2020-12-31 | 11.4B | 308M | 2B | 616M | 24.6B |
| 2019-12-31 | 11.1B | 227M | 1.4B | 582M | 23.3B |
| 2018-12-31 | 10.4B | 284M | 1.3B | 459M | 22.5B |
USD, abbreviated. Restated annual history; not a point-in-time backtest. Missing values appear as dashes.
Trace the inputs
MODEL ANNUAL PERIOD| Input | Value | SEC tag / source | Filed |
|---|---|---|---|
| revenue | 16.3B | RevenueFromContractWithCustomerExcludingAssessedTax | 2026-02-17 |
| netIncome | 1.4B | ProfitLoss Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-17 |
| Parent/common earnings proxy | 1.4B | NetIncomeLoss | 2026-02-17 |
| cfo | 2.7B | NetCashProvidedByUsedInOperatingActivities | 2026-02-17 |
| capex | 603M | PaymentsToAcquireProductiveAssets | 2026-02-17 |
| operatingIncome | 2.2B | OperatingIncomeLoss | 2026-02-17 |
| assets | 29.9B | Assets | 2026-02-17 |
| equity | 6.6B | StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Explicit consolidated amount, including the portion attributable to noncontrolling interests. | 2026-02-17 |
| Parent book equity proxy | 6.5B | StockholdersEquity | 2026-02-17 |
| debt | 15.7B | LongTermDebtCurrent + LongTermDebtNoncurrent | 2026-02-17 |
| shortDebt | — | Not reported under a supported tag | — |
| cash | 2B | CashAndCashEquivalentsAtCarryingValue | 2026-02-17 |
| shares | 173.5M | WeightedAverageNumberOfDilutedSharesOutstanding | 2026-02-17 |
| dividends | — | Not reported under a supported tag | — |
| buybacks | 1.2B | PaymentsForRepurchaseOfCommonStock | 2026-02-17 |
| issuance | — | Not reported under a supported tag | — |